Current Report Filing (8-k)
13 Avril 2023 - 10:20PM
Edgar (US Regulatory)
0001513525
false
0001513525
2023-04-12
2023-04-12
0001513525
us-gaap:CommonStockMember
2023-04-12
2023-04-12
0001513525
ADIL:WarrantsMember
2023-04-12
2023-04-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (date of earliest event reported): April
12, 2023
Adial Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
001-38323 |
|
82-3074668 |
(Commission File Number) |
|
(IRS Employer Identification No.) |
1180 Seminole Trail, Suite 495
Charlottesville, Virginia 22901
(Address of principal executive offices and zip
code)
(434) 422-9800
(Registrant’s telephone number including area
code)
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbols |
|
Name of each exchange on which registered |
Common Stock |
|
ADIL |
|
NASDAQ |
|
|
|
|
|
Warrants |
|
ADILW |
|
NASDAQ |
Indicate by check mark whether the registrant is an
emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07. |
Submission of Matters to a Vote of Security Holders. |
On April 12, 2023, Adial
Pharmaceuticals, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”) at which
the Company’s stockholders voted on two (2) proposals (the “Proposals”) and cast their votes as described below. These
Proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A for the Special Meeting that
was initially filed with the Securities and Exchange Commission (“SEC”) on March 6, 2023, as supplemented by the filing with
the SEC of definitive additional materials on March 29, 2023 (the “Definitive Proxy Statement”).
At the Special Meeting, the
Company’s stockholders were asked to vote on the following two (2) Proposals:
Proposal 1: Approval
of an amendment to the Company’s Certificate of Incorporation (the “Certificate of Incorporation”), at the discretion
of the Board of Directors of the Company (the “Board”), to effect a reverse stock split (the “Reverse Stock Split”)
with respect to the Company’s issued and outstanding common stock, par value $0.001 per share (“Common Stock”), including
stock held by the Company as treasury shares, at a ratio in the range of 1-for-2 to 1-for-50, with the ratio within such range to
be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement. This
proposal is referred to as the “Reverse Stock Split Proposal” or “Proposal 1.”
The stockholders approved
Proposal 1 to amend the Certificate of Incorporation based on the votes listed below:
Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non-Votes | |
| 16,585,304 | | |
| 2,050,482 | | |
| 28,565 | | |
| - | |
If
the Board determines that it is in the best interests of the Company and its stockholders to implement a Reverse Stock Split at a particular
date, the Board will determine the ratio, within the range approved by the Company’s stockholders, of the Reverse Stock Split and
implement such Reverse Stock Split by filing a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Certificate
of Amendment”) with the Secretary of State of the State of Delaware. Such Reverse Stock Split, if any, will become effective after
the filing of the Certificate of Amendment on the effective date determined by the Board and set forth in the Certificate of Amendment.
If the Board does not implement the Reverse Stock Split prior to the one-year anniversary of the Special Meeting, the authority granted
to the Board to implement the Reverse Stock Split will terminate and the Reverse Stock Split will be abandoned.
Proposal 2: Approval
of an adjournment of the Special Meeting to a later date, if necessary, to permit further solicitation and vote of proxies in the event
there are not sufficient votes in favor of the Reverse Stock Split Proposal. This proposal is referred to as the “Adjournment Proposal”
or “Proposal 2.” The Adjournment Proposal was presented at the Special Meeting but not needed as Proposal 1 received a sufficient
number of votes for approval.
The stockholders approved
Proposal 2 based on the votes listed below:
Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non-Votes | |
| 17,465,868 | | |
| 1,135,263 | | |
| 63,222 | | |
| - | |
Item 9.01. |
Financial Statements and Exhibits. |
Exhibit
Number |
|
Description |
104 |
|
Cover Page Interactive Data File (embedded within the XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 13, 2023 |
ADIAL PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/ Cary J. Claiborne |
|
Name: |
Cary J. Claiborne |
|
Title: |
President and Chief Executive Officer |
Adial Pharmaceuticals (NASDAQ:ADIL)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Adial Pharmaceuticals (NASDAQ:ADIL)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025